Work

Abstract P039: A phase 1 dose escalation study of protein arginine methyltransferase 5 (PRMT5) inhibitor PRT543 in patients with advanced solid tumors and lymphoma

Year: 2021

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-21-p039

Authors: Meredith McKean, Manish R. Patel, Robert Wesolowski, Renata Ferrarotto, Eytan M. Stein, Alexander N. Shoushtari, David Mauro, John Viscusi, Peggy Scherle, Neha Bhagwat, William Sun, Rachel Chiaverelli, Eric Mintah, Shekeab Jauhari, Laura Finn, Neil D. Palmisiano, Robert A. Baiocchi

Institutions: Tennessee Oncology, Florida Cancer Specialists & Research Institute, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Prelude Therapeutics Incorporated (United States), Ochsner Health System, Thomas Jefferson University, Sidney Kimmel Cancer Center

Language: English

Topic: Cancer-related gene regulation

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4200420960

Cites:

Cited by: 18

Related to: 10